Next-Generation Oncolytic Virus Platform for Personalized Cancer Therapy

A comprehensive platform integrating genetically engineered oncolytic viruses, machine learning algorithms, and nanocarriers for targeted and personalized cancer treatment, enabling more effective and efficient therapies.

The original patent disclosed a method for enhancing an antitumor effect of a coxsackievirus using oxaliplatin. However, this approach has limitations in terms of selectivity, efficacy, and patient-specific variability. The new inventive concept addresses these limitations by introducing a paradigm shift in oncolytic virus therapy, leveraging advanced technologies to create a more sophisticated and adaptable platform.

The next-generation oncolytic virus platform consists of several key components: (1) genetically engineered oncolytic viruses capable of selectively infecting and killing cancer cells, (2) machine learning algorithms for predicting optimal treatment strategies for individual patients, (3) nanocarriers for targeted delivery of the viruses, and (4) devices for in vivo production and purification of the viruses. This integrated platform enables real-time monitoring, adaptive treatment, and personalized therapy, overcoming the limitations of traditional oncolytic virus therapies.

The new inventive concept introduces a novel combination of advanced technologies, including genetic engineering, machine learning, and nanotechnology, to create a more effective, efficient, and adaptable oncolytic virus platform. The inventive step lies in the integration of these technologies to address the limitations of traditional oncolytic virus therapies, providing a more comprehensive and personalized approach to cancer treatment.

Alternative embodiments of the platform could include the use of different types of viruses, varying nanocarrier designs, or alternative machine learning algorithms. Variations could also involve integrating additional components, such as immune checkpoint inhibitors or biosensors, to further enhance the platform's efficacy and versatility.

The next-generation oncolytic virus platform has significant commercial potential in the cancer therapy market, with applications in personalized medicine, targeted therapy, and companion diagnostics. The platform's adaptability and versatility make it an attractive solution for pharmaceutical companies, biotech startups, and research institutions seeking to develop more effective and efficient cancer treatments.